Altered endothelin-1 binding following balloon angioplasty of pig coronary arteries: effect of the ETA receptor antagonist, LU 135252.
OBJECTIVE
Since raised levels of endothelin-1 (ET-1) have been detected in the human coronary sinus following percutaneous transluminal angioplasty (PTCA) we investigated the role of ET-1 in the etiology of vascular restenosis.


METHODS
Balloon angioplasty of coronary arteries was performed in pigs and the animals were treated with placebo or the endothelin (ETA) receptor antagonist LU 135252 (30 mg/kg/day). After 4 weeks vascular stenosis and the distribution of endothelin and its receptors was evaluated.


RESULTS
The pronounced neointima formation in the control group (neointima:media ratio = 0.87 +/- 0.36) was significantly reduced by LU 135252 (0.43 +/- 0.30, P < 0.001). Angioplasty caused a significant increase in medial ETA (approximately 275%, P < 0.026) and ETB (approximately 250%, P < 0.001) binding to injured, compared with non-injured segments, an effect that was also reduced by LU 135252 (ETA = 11.5% increase; ETB = 14% increase). The neointima of control animals exhibited ET-1 like immunoreactivity as well as ETA and ETB binding sites.


CONCLUSIONS
These data indicate that endothelin is locally-released from endothelial and vascular smooth muscle cells following angioplasty which binds to ETA and ETB receptor sites in the neointima and media. Since administration of the ETA antagonist LU 135252 markedly reduces neointima formation and medial ET binding, we conclude that vascular smooth muscle cell proliferation and subsequent neointima formation is mediated predominantly via ETA receptors. These data underscore the therapeutic potential of ETA antagonists in reducing the degree of restenosis following vascular injury.
Dashwood
M R
MR
Department of Chemical Pathology and Human Metabolism, Royal Free Hospital School of Medicine, London, UK.
Noertersheuser
P
P
Kirchengast
M
M
Münter
K
K
D015906:Angioplasty, Balloon, Coronary; D000818:Animals; D001345:Autoradiography; D003327:Coronary Disease / Q000378:metabolism* / Q000473:pathology / Q000628:therapy; D003331:Coronary Vessels / Q000378:metabolism* / Q000473:pathology; D065128:Endothelin Receptor Antagonists; D019332:Endothelin-1 / Q000378:metabolism*; D007150:Immunohistochemistry; D010666:Phenylpropionates / Q000494:pharmacology*; D011485:Protein Binding / Q000187:drug effects; D011743:Pyrimidines / Q000494:pharmacology*; D011897:Random Allocation; D012008:Recurrence; D013552:Swine
D065128:Endothelin Receptor Antagonists; D019332:Endothelin-1; D010666:Phenylpropionates; D011743:Pyrimidines; C107831:darusentan